Capricor (CAPR) Emerges as a Top Buyout Target After Breakthrough Duchenne Data
Capricor Therapeutics Inc. (NASDAQ:CAPR) is a late-stage biotechnology company at the forefront of developing transformative cell and exosome-based…
Browsing Tag